Economic cost-benefit analysis of person-centred medicines reviews by general practice pharmacists
Loading...
Files
Published Version
Date
2024
Authors
O’Mahony, Cian
Dalton, Kieran
O’Hagan, Leon
Murphy, Kevin D.
Kinahan, Clare
Coyle, Emma
Sahm, Laura J.
Byrne, Stephen
Kirke, Ciara
Journal Title
Journal ISSN
Volume Title
Publisher
Springer Science and Business Media Deutschland GmbH
Published Version
Abstract
Background: Medicines reviews by general practice pharmacists improve patient outcomes, but little is known about the associated economic outcomes, particularly in patients at higher risk of medicines-related harm. Aim: To conduct an economic cost-benefit analysis of pharmacists providing person-centred medicines reviews to patients with hyperpolypharmacy (prescribed ≥ 10 regular medicines) and/or at high risk of medicines-related harm across multiple general practice settings. Method: Service delivery costs were calculated based on the pharmacist’s salary, recorded timings, and a general practitioner fee. Direct cost savings were calculated from the cost change of patients’ medicines post review, projected over 1 year. Indirect savings were calculated using two models, a population-based model for avoidance of hospital admissions due to adverse drug reactions and an intervention-based model applying a probability of adverse drug reaction avoidance. Sensitivity analyses were performed using varying workday scenarios. Results: Based on 1471 patients (88.4% with hyperpolypharmacy), the cost of service delivery was €153 per review. Using the population-based model, net cost savings ranging from €198 to €288 per patient review and from €73,317 to €177,696 per annum per pharmacist were calculated. Using the intervention-based model, net cost savings of €651–€741 per review, with corresponding annual savings of €240,870–€457,197 per annum per pharmacist, were calculated. Savings ratios ranged from 181 to 584% across all models and inputs. Conclusion: Person-centred medicines reviews by general practice pharmacists for patients at high risk of medicines-related harm result in substantial cost savings. Wider investment in general practice pharmacists will be beneficial to minimise both patient harm and healthcare system expenditure. © The Author(s) 2024.
Description
Keywords
Cost , General practice , Pharmacist , Pharmacoeconomics , Polypharmacy
Citation
O’Mahony, C., Dalton, K., O’Hagan, L., Murphy, K.D., Kinahan, C., Coyle, E., Sahm, L.J., Byrne, S. and Kirke, C. (2024) 'Economic cost-benefit analysis of person-centred medicines reviews by general practice pharmacists', International Journal of Clinical Pharmacy, 46(4), pp 957-965. https://doi.org/10.1007/s11096-024-01732-y